Related Experiment Videos
BMS-184476 Bristol-Myers Squibb.
1Department of Chemistry, Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA. iojima@notes.cc.sunysb.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|August 7, 2003
Summary
Bristol-Myers Squibb is developing BMS-184476, a taxane analog, for treating solid tumors. Phase II trials were underway by May 2002 for breast, ovarian, and non-small-cell lung cancers.
Area of Science:
- Oncology
- Pharmacology
Background:
- BMS-184476 is a novel taxane analog.
- It is under investigation for cancer treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of BMS-184476 in patients with solid tumors.
Main Methods:
- Phase II clinical trials were conducted.
- Studies included patients with breast, ovarian, and non-small-cell lung cancer.
Main Results:
- BMS-184476 demonstrated potential in treating various solid tumors.
Conclusions:
- BMS-184476 showed promise as a therapeutic agent for solid tumors, warranting further investigation.